Skip to content

A Comparison of Acute Pharmacological Effects of Methylone and MDMA Administration in Humans and Oral Fluid Concentrations as Biomarkers of Exposure

Lourdes Poyatos, Esther Papaseit, Eulàlia Olesti, Clara Pérez‐mañá, Mireia Ventura, Xoán Carbón, M. Grifell, Francina Fonseca, Marta Torrens, Rafael de la Torre, Magı́ Farré

Biology August 17, 2021 DOI: 10.3390/biology10080788 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational-naturalistic study Peer reviewed
Sample size 14
Population Healthy poly-drug users
Interventions Methylone MDMA
Dose 100 to 300 mg (methylone), 75 to 100 mg (MDMA)
Duration 4 hours
Topics MDMA
Keywords Cathinone Pharmacology Mephedrone Hallucinogen Methamphetamine Toxicology Anesthesia Drug
Citations 26
Key findings Methylone produces acute psychostimulant and empathogenic effects similar to MDMA but less intense, with comparable abuse potential.

Abstract

Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or published intoxication reports. In the present observational–naturalistic study, we evaluate the acute subjective and physiological effects of methylone after oral self-administration in comparison to MDMA in healthy poly-drug users. Fourteen participants (10 males, 4 females) selected their single oral doses of methylone from 100 to 300 mg (n = 8, mean dose 187.5 mg) or MDMA from 75 to 100 mg (n = 6, mean dose 87.5 mg) based on their experience. Study variables were assessed at 0, 1, 2, and 4 h (h) and included vital signs (non-invasive blood pressure, heart rate, cutaneous temperature) and subjective effects using visual analogue scales (VAS), the 49-item Addiction Research Centre Inventory (ARCI) short form, and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) questionnaire. Additionally, oral fluid concentrations of methylone and MDMA were determined. Acute pharmacological effects produced by methylone followed the prototypical psychostimulant and empathogenic profile associated with MDMA, although they were less intense. Methylone concentrations in oral fluid can be considered a useful biomarker to detect acute exposure in oral fluid. Oral fluid concentrations of MDMA and methylone peaked at 2 h and concentrations of MDMA were in the range of those previously described in controlled studies. Our results demonstrate that the potential abuse liability of methylone is similar to that of MDMA in recreational subjects.

Comparable studies

Other observational and cohort studies on MDMA, most cited first.

Study Year Design Participants
Subjective Reports of the Effects of MDMA in a Clinical Setting Individuals who took MDMA in a clinical setting 1986 Observational study
Memory impairment in abstinent MDMA ("Ecstasy") users Abstinent MDMA users 1998 Observational cohort
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people 2000 Observational
The Psychological and Physiological Effects of MDMA on Normal Volunteers Older, more educated, drug-experienced individuals 1986 Observational cohort
Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits Young people who were regular or novice MDMA users, or non-users 1998 Observational cohort n = 30

Citations in the library

Explore topics